Advertise on podcast: Skin and Joints Podcast

Part 3 of 3: Our Practical Playbook When Skin & Gut Don’t Read the Same Treatment Plan What happens when the skin is crystal clear…but the Crohn’s disease didn’t get the memo? 👀 In the final chapter of our special Derm × GI crossover conversation, our Faculty Dr. Perry Grewal and Dr. Jesse Siffledeen get practical about what happens after the prescription is written. From treat-to-target monitoring and follow-up cadence to the very real influence of insurance requirements, our experts unpack how they decide whether a therapy is truly working—and what to do when different organ systems are telling very different stories. 🧩 Great skin, active gut?🧩 Controlled IBD, stubborn psoriasis?🧩 One therapy, two diseases…or occasionally two therapies? The conversation explores how clinicians prioritize competing treatment targets without sacrificing what matters most to the patient, why success may need to be measured beyond a single organ system, and where communication between specialties becomes essential. And perhaps the simplest clinical pearl of the entire series? Ask the questions—and don’t be afraid to pick up the phone. Because when inflammatory disease crosses specialties, the best care probably should too.   🎯 Learning Objectives After listening to this episode, participants should be able to: Describe practical approaches to monitoring treatment response across dermatologic and gastrointestinal inflammatory diseases, including the role of early clinical follow-up and objective assessment.Evaluate therapeutic options when disease control differs across organ systems, such as controlled psoriasis with active IBD or controlled IBD with persistent skin disease.Discuss the limitations of organ-specific treatment targets and incorporate patient priorities, disease severity, and multisystem outcomes when defining therapeutic success.Recognize how payer and insurance requirements can influence treatment selection, reassessment schedules, access, and consideration of dual therapy.Identify key questions that dermatology and gastroenterology clinicians can ask to recognize disease manifestations outside their own specialty and facilitate timely referral.Apply practical strategies for multidisciplinary co-management, including direct clinician-to-clinician communication and collaborative treatment decision-making,🔥 In This Episode 🔬 Treat-to-target: when should you actually reassess?🎯 One patient, two organs: does success require both to be at target?🔄 Great skin, active gut—or vice versa: when do you switch?💊 Dual therapy: useful tool or access nightmare?💰 When insurance starts influencing the clinical calendar🗣️ Why asking about the gut–skin–joint connection matters📞 The underrated power of simply calling your colleague🤝 Why multidisciplinary care needs to move from concept to everyday workflow     #SkinAndJoints #Dermatology #Gastroenterology #IBD #CrohnsDisease #Psoriasis #SkinGutAxis #TreatToTarget #Biologics #IL23 #InflammatoryDisease #MultidisciplinaryCare #PrecisionMedicine #PatientCentredCare #MedicalEducation #HCPeducation     SUPPORTED BY AN IME GRANT FROM JnJ Johnson and Johnson.   ABOUT Dr. Parbeer Grewal Dermatologist, Edmonton, AB Dr. Parbeer Grewal completed his Bachelor of Science undergraduate degree at the University of Alberta with a specialization in Psychology and graduated with distinction. He completed his Doctorate of Medicine degree at the University of Alberta and graduated with Special Training in Research. He completed dermatology training at the University of Alberta and became a Fellow of the Royal College of Physicians and Surgeons of Canada and a board-certified Fellow of the American Academy of Dermatology.  Dr. Grewal is an Associate Clinical Professor within the University of Alberta’s Faculty of Medicine - Dermatology. In addition to working at Rejuvenation, he is a consulting physician for the University of Alberta Hospital, the Royal Alexandra Hospital, the Grey Nuns Hospital and the Misericordia Hospital. Dr. Grewal has participated in over 60 clinical research trials for a multitude of dermatology conditions and medications. In addition, Dr. Grewal serves on multiple national and international scientific advisory boards, is a distinguished peer reviewer for medical journals and has published both journal articles and book chapters in dermatology.  He has specific interests in psoriasis, acne, eczema, warts, skin cancers, rashes and moles. He offers a wide range of topical and systemic therapy along with surgical and aesthetic services.   ABOUT Dr. Jesse Siffledeen, MD, FRCPC Gastroenterology, Edmonton, AB Dr. Siffledeen is a clinical professor in the Division of Gastroenterology at the University of Alberta. He is also currently the past-president of the Alberta Society of Gastroenterology. He has established a large clinical IBD practice in Edmonton and is the director of the South Edmonton Gastroenterology Research Unit, serving as principal investigator and collaborator on several IBD-related clinical trials for over 20 years.  He is an active collaborator in the Edmonton IBD research community and as a member of the Canadian IBD research consortium. Dr. Siffledeen completed his Gastroenterology studies at the University of Alberta in 2010 and inflammatory bowel disease research/Master’s degree at the University of Oxford in 2011.  📻www.skinandjoints.ca ✉️[email protected]

🎙️ Beyond Skin Deep & Gut Feelings — Part 2: When the Gut and Skin Share the Treatment Plan One patient. Two organ systems. And suddenly, choosing a biologic gets a whole lot more interesting. 👀 In Part 2 of our Derm × GI crossover, podcast Faculty members dermatologist Dr. Perry Grewal and gastroenterologist Dr. Jesse Siffledeen move from diagnosis into the real-world treatment decisions that happen when psoriasis and inflammatory bowel disease collide. PRO-TIPS COVERED: How do you practically choose one therapy when you’re treating two inflammatory diseases? When might suspected IBD steer a dermatologist away from an IL-17 inhibitor? What happens when the dose needed for Crohn’s disease doesn’t match the dose used for psoriasis? And when one drug isn’t enough, is dual advanced therapy the next frontier—or an insurance headache waiting to happen? 😅 The conversation also digs into the very different therapeutic ceilings in dermatology and gastroenterology, including emerging data in perianal Crohn’s disease, the challenge of achieving true mucosal healing, and why GI may still be chasing remission rates that dermatology has already learned to expect from modern psoriasis therapy. It gets practical: Who owns the prescription? Who takes the lead when one organ system flares? How much communication is really needed between specialists? And where do vaccinations fit when advanced therapy needs to start quickly? From IL-23s vs IL-17s to biologic dosing, multidisciplinary care, vaccine timing and the occasional therapeutic turf war, this is where “shared care” leaves the PowerPoint slide and enters actual clinical practice. 🧩 🎯 Learning Objectives After listening to this episode, participants should be able to: Compare key clinical factors that influence advanced therapy selection in patients with psoriasis and coexisting or suspected inflammatory bowel disease.Explain how IL-17, IL-23 and TNF-targeted therapies may be approached differently when Crohn’s disease, fistulizing disease or possible IBD is part of the clinical picture.Discuss real-world challenges in multidisciplinary treatment, including differing doses across indications, prescription ownership, reimbursement barriers and situations where dual advanced therapy may be considered.Contrast treatment targets in psoriasis and IBD, including PASI-based skin clearance versus clinical remission, endoscopic improvement and mucosal healing.Identify practical approaches to vaccination and treatment onboarding for patients starting biologic or other advanced systemic therapies.🎧 Part 2 of 3 — stay tuned for Part 3 as the conversation moves into monitoring and treat-to-target across the skin–gut axis. #SkinAndJoints #Dermatology #Gastroenterology #IBD #CrohnsDisease #Psoriasis #SkinGutAxis #Biologics #IL23 #IL17 #TNFInhibitors #InflammatoryDisease #PrecisionMedicine #MultidisciplinaryCare #MedicalEducation #HCPeducation 🧬🩺💊   SUPPORTED BY AN IME GRANT FROM JnJ Johnson and Johnson.   ABOUT Dr. Parbeer Grewal Dermatologist, Edmonton, AB Dr. Parbeer Grewal completed his Bachelor of Science undergraduate degree at the University of Alberta with a specialization in Psychology and graduated with distinction. He completed his Doctorate of Medicine degree at the University of Alberta and graduated with Special Training in Research. He completed dermatology training at the University of Alberta and became a Fellow of the Royal College of Physicians and Surgeons of Canada and a board-certified Fellow of the American Academy of Dermatology.  Dr. Grewal is an Associate Clinical Professor within the University of Alberta’s Faculty of Medicine - Dermatology. In addition to working at Rejuvenation, he is a consulting physician for the University of Alberta Hospital, the Royal Alexandra Hospital, the Grey Nuns Hospital and the Misericordia Hospital. Dr. Grewal has participated in over 60 clinical research trials for a multitude of dermatology conditions and medications. In addition, Dr. Grewal serves on multiple national and international scientific advisory boards, is a distinguished peer reviewer for medical journals and has published both journal articles and book chapters in dermatology.  He has specific interests in psoriasis, acne, eczema, warts, skin cancers, rashes and moles. He offers a wide range of topical and systemic therapy along with surgical and aesthetic services.   ABOUT Dr. Jesse Siffledeen, MD, FRCPC Gastroenterology, Edmonton, AB Dr. Siffledeen is a clinical professor in the Division of Gastroenterology at the University of Alberta. He is also currently the past-president of the Alberta Society of Gastroenterology. He has established a large clinical IBD practice in Edmonton and is the director of the South Edmonton Gastroenterology Research Unit, serving as principal investigator and collaborator on several IBD-related clinical trials for over 20 years.  He is an active collaborator in the Edmonton IBD research community and as a member of the Canadian IBD research consortium. Dr. Siffledeen completed his Gastroenterology studies at the University of Alberta in 2010 and inflammatory bowel disease research/Master’s degree at the University of Oxford in 2011.  📻www.skinandjoints.ca ✉️[email protected] 📻www.skinandjoints.ca ✉️[email protected]

Not every loose stool is Crohn’s. Not every rash is “just a rash.” And sometimes the most useful clinical tool is knowing exactly which colleague to text. In Part 1 of our special Skin and Joints Podcast crossover, we go beyond skin deep and gut feelings with dermatologist Dr. Perry Grewal and gastroenterologist Dr. Jesse Siffledeen to tackle what Derm–GI collaboration actually looks like, or could look like in the real world. Psoriasis and inflammatory bowel disease may live in different specialty clinics, but for many patients, the boundaries aren’t nearly so tidy. What should make a dermatologist start thinking about the gut? Which GI symptoms deserve a routine referral—and which ones should make your clinical “spidey sense” start tingling? Our guest experts get practical about: 🔎 The GI red flags worth screening for in patients with psoriatic disease🚨 When a referral can wait—and when it probably shouldn’t🧪 Where fecal calprotectin, inflammatory markers and anemia fit into the picture📲 Why sometimes a colleague’s name, and a quick message can be more useful than an elaborate referral pathway📝 What actually needs to go into a useful Derm-to-GI or GI-to-Derm referral🧩 How to begin separating IBD from common mimics such as IBS and post-infectious symptoms💊 Why recognizing coexisting immune-mediated disease can influence treatment decisions And perhaps most importantly: multidisciplinary care doesn’t always require a multidisciplinary clinic. 🎯 Learning Objectives By the end of Part 1, listeners should be able to: Recognize key gastrointestinal signs, symptoms and clinical red flags that may warrant further investigation for IBD in a patient presenting with psoriatic disease.Differentiate between routine, urgent and potentially emergent GI referral scenarios based on symptoms, systemic illness and available objective findings.Describe practical strategies for Derm–GI co-management, including effective communication and the essential information to include when referring between specialties.Explain how suspected or confirmed gastrointestinal comorbidity may influence therapeutic decision-making in patients with immune-mediated disease.Identify clinical features that can help distinguish IBD from common gastrointestinal mimics, while recognizing when specialist assessment is warranted.🎧 Two specialties. One patient. And a lot more overlap than the clinic schedule might suggest. #SkinAndJointsPodcast #Dermatology #Gastroenterology #Psoriasis #IBD #CrohnsDisease #UlcerativeColitis #ImmuneMediatedDisease #MultidisciplinaryCare #MedicalEducation #DermGI #ClinicalPractice SUPPORTED BY AN IME GRANT FROM JnJ Johnson and Johnson.   ABOUT Dr. Parbeer Grewal Dermatologist, Edmonton, AB Dr. Parbeer Grewal completed his Bachelor of Science undergraduate degree at the University of Alberta with a specialization in Psychology and graduated with distinction. He completed his Doctorate of Medicine degree at the University of Alberta and graduated with Special Training in Research. He completed dermatology training at the University of Alberta and became a Fellow of the Royal College of Physicians and Surgeons of Canada and a board-certified Fellow of the American Academy of Dermatology.  Dr. Grewal is an Associate Clinical Professor within the University of Alberta’s Faculty of Medicine - Dermatology. In addition to working at Rejuvenation, he is a consulting physician for the University of Alberta Hospital, the Royal Alexandra Hospital, the Grey Nuns Hospital and the Misericordia Hospital. Dr. Grewal has participated in over 60 clinical research trials for a multitude of dermatology conditions and medications. In addition, Dr. Grewal serves on multiple national and international scientific advisory boards, is a distinguished peer reviewer for medical journals and has published both journal articles and book chapters in dermatology.  He has specific interests in psoriasis, acne, eczema, warts, skin cancers, rashes and moles. He offers a wide range of topical and systemic therapy along with surgical and aesthetic services.   ABOUT Dr. Jesse Siffledeen, MD, FRCPC Gastroenterology, Edmonton, AB Dr. Siffledeen is a clinical professor in the Division of Gastroenterology at the University of Alberta. He is also currently the past-president of the Alberta Society of Gastroenterology. He has established a large clinical IBD practice in Edmonton and is the director of the South Edmonton Gastroenterology Research Unit, serving as principal investigator and collaborator on several IBD-related clinical trials for over 20 years.  He is an active collaborator in the Edmonton IBD research community and as a member of the Canadian IBD research consortium. Dr. Siffledeen completed his Gastroenterology studies at the University of Alberta in 2010 and inflammatory bowel disease research/Master’s degree at the University of Oxford in 2011.  📻www.skinandjoints.ca ✉️[email protected]     📻www.skinandjoints.ca ✉️[email protected]

🎙️ HS & Biosimilars: The Switch Pitch — Part 3 Final drop, biggest pearls. 💎 Is HS is the new acne? How can we treat early, treat seriously, and help prevent long-term scarring—physical and emotional? In Part 3 of our real-world HS conversation, Skin and Joints Podcast F aculty Dr. Lauren Lam and Dr. Marni Wiseman bring the discussion home with practical, clinic-ready insights for dermatologists navigating biosimilars, biologics, comorbidities, obesity, smoking, PSP realities, and the art of building trust over time. From why GLP-1s are not a substitute for HS-directed biologic therapy, to how to incorporate non-stigmatizing conversations around obesity and smoking cessation in the clinic, this episode gets into the real-world nuance that does not always fit neatly into an algorithm.  And when it comes to choosing between a TNF biosimilar and IL-17 options?  How dos comorbidities, contraindications, access, PSP fit, disease severity, and the patient sitting in front of you all factor in for each? Find out here. 👩‍⚕️🧠 Learning Objectives By the end of this episode, listeners will be able to: Describe practical considerations for managing HS beyond acute flares, including longitudinal disease control and early biologic initiation in appropriate patients. Discuss how GLP-1 therapies may fit as adjunctive care in select HS patients, while recognizing that they do not replace targeted HS biologic or biosimilar therapy. Apply non-stigmatizing, patient-centred approaches when discussing obesity and smoking cessation in HS care. Identify key factors that influence selection between TNF biosimilars and IL-17 therapies, including comorbid IBD, rheumatoid arthritis, contraindications, candidiasis risk, disease severity, and access. Recognize the role of PSPs, samples, dose optimization, and follow-up planning in improving real-world HS treatment continuity.   #SkinAndJointsPodcast #HidradenitisSuppurativa #HSawareness #Dermatology #Biosimilars #Biologics #InflammatorySkinDisease #MedicalEducation #DermTwitter #DermatologyEducation #PatientCentredCare #RealWorldDermatology #PSP #IL17 #TNF #ClinicalPearls 💉🧬🎙️   ABOUT Dr. Lauren Lam BScH, MD, FRCPC ​​Medical, Surgical & Cosmetic Dermatologist CALGARY, AB Dr. Lam is the Vice President of the Canadian Hidradenitis Suppurativa Foundation and a Canadian Board Certified Dermatologist subspecializing in Hidradenitis Suppurativa Deroofing Procedures.  She runs a weekly deroofing clinic in Calgary, Alberta, and has done 1500+ cases to date.   Besides collaborating on global HS projects, her other favourite endeavours include being an international explorer, culinary enthusiast and aunt to 5 dogs.   ABOUT Dr. Marni C. Wiseman MD FRCPC DABD Associate Professor, Section Head Dermatology University of Manitoba Director, SKiNWISE DERMATOLOGY and Wiseman Dermatology Research Dr. Marni C. Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001.She is an Associate Professor and Section Head of Dermatology at the Faculty of Medicine at the University of Manitoba. Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY, where she conducts her private medical practice.   Dr. Wiseman’s areas of clinical and research interest include inflammatory disease: psoriasis, atopic dermatitis, hidradenitis suppuritiva, vitiligo, alopecia areata, urticaria, and acne vulgaris. Dr Wiseman is Principal Investigator at Wiseman Dermatology Research and has participated in hundreds of clinical trials and registry studies. Dr. Wiseman is a frequent lecturer at meetings and congresses nationally and internationally and is extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy. Dr. Wiseman is a supervisor and mentor for medical students and residents, conducts regular rural/remote outreach clinics, has significant volunteer involvement with the Canadian Dermatology Association, the Canadian Hidradenitis Suppuritiva Foundation, and is an editor of the Journal of Cutaneous Medicine and Surgery.   EPISODE SUPPORTED BY CELLTRION CANADA       📻www.skinandjoints.ca ✉️[email protected]     📻www.skinandjoints.ca ✉️[email protected]

🎙️ PART 2:  HS & Biosimilars: The Switch Pitch — Real-World Pearls from the Clinic 💉🔥🧴 In Part 2 of our HS and biosimilars conversation, we’re getting practical — very practical. 🎧🩺 Faculty Dr. Lauren Lam and Dr. Marni Wiseman join the Skin and Joints Podcast to unpack what really matters when biosimilars move from policy, paperwork, and prescribing forms… into the real lives of patients with hidradenitis suppurativa. 📋➡️💪 From the science of biosimilarity and extrapolating evidence across inflammatory diseases, to the clinic-level details dermatologists cannot afford to overlook — injection pain, citrate-free formulations, device ergonomics, dosing convenience, patient support programs, rural drug delivery, reload strategies, and yes… whether the PSP actually calls the patient back. ☎️🚚💉 Because in HS, the best biologic or biosimilar is not just about the molecule. It is about momentum, access, trust, support, and getting treatment into the patient’s hands before they disappear from the care journey. 🧭🤝 The conversation also takes a timely turn into obesity, systemic inflammation, GLP-1/GIP therapies, and whether metabolic care may become part of the next frontier in HS management. ⚖️🔥🔬 Consider this your field guide to biosimilar switching in HS — with clinic hot tips, PSP reality checks, and a reminder that sometimes the smallest formulation detail can make the biggest difference to the person injecting every week. 💡💉🙌   Learning Objectives: By the end of this episode, listeners will be able to: Explain how biosimilar evidence may be extrapolated across inflammatory diseases and how this applies to real-world HS care. 🔬 Identify key formulation and device factors that may influence patient comfort, adherence, and treatment experience with adalimumab biosimilars. 💉 Describe the role of patient support programs (PSPs) in treatment initiation, onboarding, access, monitoring, and long-term engagement for patients with HS. 🤝 Recognize practical barriers to biosimilar use in HS, including injection training, treatment delays, rural/remote medication delivery, and patient disillusionment. 🚚 Discuss emerging considerations around obesity, systemic inflammation, and GLP-1/GIP therapies as part of the evolving HS care conversation. ⚖️🔥= #SkinAndJointsPodcast #HidradenitisSuppurativa #HSawareness #Dermatology #MedicalDermatology #Biosimilars #Adalimumab #InflammatorySkinDisease #DermatologistEducation #RealWorldDermatology #PatientSupportPrograms #Biologics #ClinicalPearls #DermatologyPodcast #HSManagement 🧴💉🔥🎧🩺   ABOUT Dr. Lauren Lam BScH, MD, FRCPC ​​Medical, Surgical & Cosmetic Dermatologist CALGARY, AB Dr. Lam is the Vice President of the Canadian Hidradenitis Suppurativa Foundation and a Canadian Board Certified Dermatologist subspecializing in Hidradenitis Suppurativa Deroofing Procedures.  She runs a weekly deroofing clinic in Calgary, Alberta, and has done 1500+ cases to date.   Besides collaborating on global HS projects, her other favourite endeavours include being an international explorer, culinary enthusiast and aunt to 5 dogs.   ABOUT Dr. Marni C. Wiseman MD FRCPC DABD Associate Professor, Section Head Dermatology University of Manitoba Director, SKiNWISE DERMATOLOGY and Wiseman Dermatology Research Dr. Marni C. Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001.She is an Associate Professor and Section Head of Dermatology at the Faculty of Medicine at the University of Manitoba. Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY, where she conducts her private medical practice.   Dr. Wiseman’s areas of clinical and research interest include inflammatory disease: psoriasis, atopic dermatitis, hidradenitis suppuritiva, vitiligo, alopecia areata, urticaria, and acne vulgaris. Dr Wiseman is Principal Investigator at Wiseman Dermatology Research and has participated in hundreds of clinical trials and registry studies. Dr. Wiseman is a frequent lecturer at meetings and congresses nationally and internationally and is extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy. Dr. Wiseman is a supervisor and mentor for medical students and residents, conducts regular rural/remote outreach clinics, has significant volunteer involvement with the Canadian Dermatology Association, the Canadian Hidradenitis Suppuritiva Foundation, and is an editor of the Journal of Cutaneous Medicine and Surgery.   EPISODE SUPPORTED BY CELLTRION CANADA       📻www.skinandjoints.ca ✉️[email protected]     📻www.skinandjoints.ca ✉️[email protected]

🎙️🇨🇦🇺🇸. Hands On, Gloves Off: Cross-Border Talk on Atopic Hand Eczema We’re coming to you from the heart of Music City, Nashville 🎸 — but don’t worry, this Cross-Border Talk is not about trade, tariffs, or hockey rivalries. This time, it’s all hands on deck. ✋🇨🇦🇺🇸 In this episode of the Skin and Joints Podcast from RAD 2026, our Cross-Border Dermatologist Faculty Dr. Raj Chovatiya from the U.S. joins Canadian favourite Dr. Melinda Gooderham for a lively, practical, and focused conversation on atopic hand eczema, chronic hand eczema, and fresh week 32 data exploring tralokinumab in this challenging and high-burden body site. Hands may represent a small body surface area, but they carry an outsized burden. They are exposed, functional, visible, constantly irritated, and central to work, hobbies, caregiving, gardening, handshakes, procedures, and everyday life.  In other words: when the hands are flaring, patients are not just uncomfortable — they are often functionally sidelined. 🧤🌱 This episode goes beyond the usual did the trial hit the endpoint discussion and digs into the real-world so what? You’ll hear how the week 32 data may help frame expectations, why some patients may need more time before being labelled non-responders, how itch and pain improvements matter alongside clearance, and how shared decision-making can turn clinical trial endpoints into conversations patients actually understand. 📊🩺 The discussion also gets practical on where tralokinumab may fit alongside emerging topical options like delgocitinib, how to think about atopic hand eczema versus broader chronic hand eczema phenotypes, and why a back to basics approach remains timeless advice when patients are not responding as expected. 🔍 From Nashville notes to Monday morning clinic, this Cross-Border Talk offers a hands-on look at atopic hand eczema — with just enough clinical soil turned over to leave you wanting the full episode. 🎙️✋   Learning Objectives 🎯 After listening to this episode, listeners will be able to: Describe the clinical and functional burden of atopic hand eczema✋, including why hands represent a uniquely challenging and high-impact treatment site despite limited body surface area involvement. Summarize key elements of the week 32 tralokinumab data in atopic hand eczema📊, including trial design, patient population, efficacy signals, symptom outcomes, and tolerability considerations. Interpret week 16 versus week 32 response data through a real-world clinical lens🕒, including how to counsel partial responders and avoid prematurely labelling treatment as failure. Integrate patient-reported outcomes into treatment decision-making🗣️, particularly itch, pain, function, visibility, and the patient’s ability to return to meaningful daily activities. Differentiate treatment considerations for atopic hand eczema versus broader chronic hand eczema🧩, including when topical, systemic, or combination strategies may be appropriate. Apply practical clinic-based reassessment strategies for patients with persistent hand eczema🔍, including evaluation for irritant contact dermatitis, allergic contact dermatitis, occupational exposures, and ongoing trigger management.   ABOUT Dr. Raj Chovatiya, MD, PhD, MSCI Associate Professor | Rosalind Franklin University of Medicine and Science Chicago Medical School Founder and Director | Center for Medical Dermatology + Immunology Research Chicago, USA   Raj Chovatiya, MD, PhD, MSCI is Associate Professor at Rosalind Franklin University of Medicine and Science Chicago Medical School and Founder and Director of the Center for Medical Dermatology + Immunology Research in Chicago, Illinois. His clinical and research focus includes the intersection of cutaneous immunology and inflammatory disease. He received his MD and PhD in immunology from Yale and completed his residency, postdoctoral research fellowship, and MS in Clinical Investigation at Northwestern University where he also served as Chief Resident. Dr. Chovatiya has a particular interest in optimizing patient-centered care, understanding chronic disease burden especially in understudied inflammatory diseases, exploring health and social disparities, and improving care across diverse skin types. He has published numerous abstracts and manuscripts and has been nationally and internationally recognized for his contributions as a clinician, educator, researcher, and leader.     ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology) Toronto, ON Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada. Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.   Episode supported by and IME Grant from LEO Pharma 📻www.skinandjoints.ca ✉️[email protected]     📻www.skinandjoints.ca ✉️[email protected]

🎙️ PART 1:  Real-World Biosimilar Care in HS with Dr. Lauren Lam and Dr. Marni Wiseman HS has officially entered the Skin and Joints chat — and it did not come quietly. In this special Part 1 episode, we welcome back two Skin and Joints Podcast Faculty favourites, dermatologists Dr. Lauren Lam and Dr. Marni Wiseman, for a practical, candid, and refreshingly real-world conversation on hidradenitis suppurativa, biologics, and the evolving role of biosimilars in Canadian care. From delayed diagnosis and cumulative life-course impact to biologic timing, patient expectations, injection burden, access barriers, and the art of asking, “How sick of this are you?” — this episode digs into the clinical realities that do not always fit neatly into trial endpoints. Dr. Lam and Dr. Wiseman share frontline insights on why HS is uniquely challenging, why earlier intervention may change the patient journey, and how biosimilars are reshaping access, dosing conversations, and practical treatment decisions. Expect clinical pearls, a few myth-busting moments, and clinic hot tips you can actually use — from identifying the right referral pathway, to setting realistic goals, minimizing injection burden, considering dose optimization, and translating trial endpoints into real-life wins for patients. Also discussed: tennis dreams, cottage shade, citrate-free formulations, the joy of one injection instead of two, and why HS care is rarely a solo sport. 🎾🌿💉 Learning Objectives After listening to this episode, learners should be able to: Describe why hidradenitis suppurativa is uniquely challenging to manage compared with other chronic inflammatory skin diseases, including the role of delayed diagnosis, comorbidities, surgery, pain, drainage, scarring, and quality-of-life burden. Identify real-world factors that influence biologic initiation in HS, particularly in moderate disease, including patient-reported impact, flare burden, treatment goals, and the importance of earlier intervention when clinically appropriate. Explain the current relevance of adalimumab biosimilars in Canadian HS care, including access, reimbursement, compassionate support, patient counselling, and confidence in biosimilar efficacy and safety. Apply practical counselling strategies for patients starting or switching to biosimilar therapy, including how to discuss expectations, injection burden, pain, formulation differences, and meaningful patient-centred outcomes. Recognize clinic-ready strategies to optimize HS care, including referral tips, patient-centred goal setting, realistic timelines for improvement, combination therapy considerations, and individualized dose optimization in patients with persistent disease activity. #SkinAndJointsPodcast #HidradenitisSuppurativa #HSAwareness #Biosimilars #Adalimumab #Dermatology #RheumDerm #InflammatoryDisease #RealWorldEvidence #PatientCenteredCare #BiologicTherapy #CanadianDermatology #MedicalPodcast #ClinicianEducation #ClinicHotTips #AccessToCare Episode supported by Celltrion Canada.     ABOUT Dr. Lauren Lam BScH, MD, FRCPC ​​Medical, Surgical & Cosmetic Dermatologist CALGARY, AB Dr. Lam is the Vice President of the Canadian Hidradenitis Suppurativa Foundation and a Canadian Board Certified Dermatologist subspecializing in Hidradenitis Suppurativa Deroofing Procedures.  She runs a weekly deroofing clinic in Calgary, Alberta, and has done 1500+ cases to date.   Besides collaborating on global HS projects, her other favourite endeavours include being an international explorer, culinary enthusiast and aunt to 5 dogs.   ABOUT Dr. Marni C. Wiseman MD FRCPC DABD Associate Professor, Section Head Dermatology University of Manitoba Director, SKiNWISE DERMATOLOGY and Wiseman Dermatology Research Dr. Marni C. Wiseman began her Dermatology practice in Winnipeg, Manitoba in 2001.She is an Associate Professor and Section Head of Dermatology at the Faculty of Medicine at the University of Manitoba. Dr. Wiseman is the Medical Director of SKiNWISE DERMATOLOGY, where she conducts her private medical practice.   Dr. Wiseman’s areas of clinical and research interest include inflammatory disease: psoriasis, atopic dermatitis, hidradenitis suppuritiva, vitiligo, alopecia areata, urticaria, and acne vulgaris. Dr Wiseman is Principal Investigator at Wiseman Dermatology Research and has participated in hundreds of clinical trials and registry studies. Dr. Wiseman is a frequent lecturer at meetings and congresses nationally and internationally and is extensively published in areas of inflammatory skin disease, photodermatosis, and cutaneous malignancy. Dr. Wiseman is a supervisor and mentor for medical students and residents, conducts regular rural/remote outreach clinics, has significant volunteer involvement with the Canadian Dermatology Association, the Canadian Hidradenitis Suppuritiva Foundation, and is an editor of the Journal of Cutaneous Medicine and Surgery.   EPISODE SUPPORTED BY CELLTRION CANADA       📻www.skinandjoints.ca ✉️[email protected]     📻www.skinandjoints.ca ✉️[email protected]

🎙️The Great Dose Debate: Escalate, De-escalate, or Hold Steady? In this final episode of our AAD 2026 atopic dermatitis post-game poster series, we’re joined by dermatologist Dr. Julien Ringuet from Quebec City for a practical, no-fluff breakdown of the JADE REAL analysis — and what flexible abrocitinib dosing may actually mean when Monday morning clinic rolls around. Because in real life, patients do not always follow a tidy trial algorithm. Symptoms flare, itch keeps people up, adherence shifts, priorities change, and sometimes the “right” dose is less of a fixed destination and more of a GPS recalculating in real time. 🧭 Dr. Ringuet walks us through the clinical “so what” behind dose escalation and de-escalation, explaining why moving from 100 mg to 200 mg — or stepping down from 200 mg to 100 mg — should not automatically be seen as failure, overtreatment, or backpedalling.  Instead, flexible dosing may be part of a thoughtful, shared decision-making strategy that better reflects the messy, dynamic reality of moderate-to-severe atopic dermatitis care. We cover how early reassessment, patient-reported outcomes, itch, sleep, EASI trends, payer flexibility, and treat-to-target thinking all fit into the bigger picture. And yes, we also discuss the real-world art of knowing when to push, when to pause, and when to test the waters with a lower dose. 🌊   ✨ Learning Objectives By the end of this episode, listeners should be able to: Describe how the JADE REAL study design reflects real-world clinical decision-making in moderate-to-severe atopic dermatitis. Explain why dose escalation and de-escalation with abrocitinib may represent intentional treatment optimization rather than treatment failure. Identify practical clinical scenarios where starting at 100 mg versus 200 mg may be appropriate. Discuss how early follow-up, patient-reported outcomes, itch, sleep, and quality-of-life measures can help guide dose adjustment decisions. Recognize key limitations of open-label, real-world evidence when translating study findings into clinical practice. Apply a treat-and-adjust approach to atopic dermatitis management using shared decision-making and individualized treatment goals.   💡 Key Takeaway Flexible dosing is not a loophole — it is real-world dermatology. The win is not finding one perfect pathway for every patient; it is learning how to reassess early, individualize thoughtfully, and adjust with purpose. 🩺 🎧 Tune in for practical pearls, real-world nuance, and Dr. Ringuet’s post-game analysis on what these data may mean for dermatologists managing AD in everyday practice.   #SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #EczemaCare #Dermatology #PatientReportedOutcomes #JAKInhibitors #abrocitinib  #DermatologyEducation #MedicalEducation #HCPeducation #TreatToTarget #InflammatorySkinDisease #ClinicalData #DermTwitter #MedEd #Vodcast #PodcastEpisode #AADDenver #JAK #JAKinhibitor   ABOUT Dr. Julien Ringuet Dermatologist, Quebec City, QC Dr Ringuet is a board certified dermatologist who practices in Quebec City as the principal investigator at the Centre de Recherche Dermatologique de Québec (CRDQ). He completed his medical training (MD) and his post graduate studies in dermatology form Laval University as well as a master in experimental medicine (MSc.) in the field of skin bioengineering at the Laboratoire d’Organogénèse Expérimentale de l’Université Laval (LOEX/CMDGT). Dr Ringuet and his team of the CRDQ are allowing patient access to quality and innovative clinical research focused on alopecia areata, atopic dermatitis, psoriasis and its variants and vitiligo.   Supported by an IME Grant from PFIZER.         📻www.skinandjoints.ca ✉️[email protected]

From Clearer Skin to Better Sleep: MDA and Redefining Success in Atopic Dermatitis 🎙️ Are We Treating Eczema… or Just Admiring Better Scores? Minimal Disease Activity in Atopic Dermatitis In this rapid-fire AAD poster recap, dermatologist Dr. Julien Ringuet joins the Skin and Joints podcast to unpack a big idea with a small acronym: MDA — Minimal Disease Activity. Borrowed from the rheumatology playbook and now making its way into dermatology, MDA asks a deceptively simple question in atopic dermatitis care: Is the patient actually doing well, or do they just look better on paper? Together, we dive into new treat-to-target data from the AHEAD analysis, comparing abrocitinib and dupilumab through a more holistic lens — one that includes not only skin clearance, but also itch, sleep, quality of life, and the patient’s lived experience. Spoiler: an EASI score may be impressive, but it does not tuck your patient into bed at night. Dr. Ringuet breaks down how MDA could help clinicians raise the bar in atopic dermatitis management, why early symptom relief matters, where oral JAK inhibitors may fit for selected patients, and why safety, comorbidities, route of administration, patient preference, and long-term strategy still deserve front-row seats in every treatment decision. This episode is not just about picking a winner between therapies. It is about redefining what “success” should mean in chronic inflammatory skin disease — and avoiding the trap of accepting “better” when patients are still itchy, sleepless, and sidelined from daily life. 🎯 Learning Objectives By the end of this episode, listeners will be able to: Define Minimal Disease Activity in atopic dermatitis using the AHEAD treat-to-target framework, including both clinician-reported and patient-reported outcomes. Explain why MDA may offer a more patient-centred endpoint than traditional skin-only measures such as EASI 75 or EASI 90. Interpret key findings from the abrocitinib versus dupilumab analysis, including the relevance of early response, week-two separation, and multidimensional disease control. Identify patient profiles where rapid and comprehensive symptom control may influence treatment selection, while balancing safety, comorbidities, monitoring needs, access, and patient preferences. Describe practical ways to integrate a treat-to-target MDA approach into dermatology clinics, using manageable tools such as IGA/BSA or EASI, itch NRS, sleep NRS, and DLQI. Recognize the importance of avoiding therapeutic inertia when patients remain itchy, sleep-deprived, or functionally impaired despite partial improvement. 🧠 Key Takeaway Minimal Disease Activity may be the dermatology upgrade we did not know we needed: less “your skin looks better” and more “are you sleeping, functioning, and living better?” #SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #EczemaCare #Dermatology #PatientReportedOutcomes #JAKInhibitors #abrocitinib  #DermatologyEducation #MedicalEducation #HCPeducation #TreatToTarget #InflammatorySkinDisease #ClinicalData #DermTwitter #MedEd #Vodcast #PodcastEpisode #AADDenver #JAK #JAKinhibitor   ABOUT Dr. Julien Ringuet Dermatologist, Quebec City, QC Dr Ringuet is a board certified dermatologist who practices in Quebec City as the principal investigator at the Centre de Recherche Dermatologique de Québec (CRDQ). He completed his medical training (MD) and his post graduate studies in dermatology form Laval University as well as a master in experimental medicine (MSc.) in the field of skin bioengineering at the Laboratoire d’Organogénèse Expérimentale de l’Université Laval (LOEX/CMDGT). Dr Ringuet and his team of the CRDQ are allowing patient access to quality and innovative clinical research focused on alopecia areata, atopic dermatitis, psoriasis and its variants and vitiligo.   Supported by an IME Grant from PFIZER.         📻www.skinandjoints.ca ✉️[email protected]

JAKs, Flares & Rescue Plans:  The Art of the Atopic Dermatitis Dose-Down 🎙️ In this rapid-fire post-AAD recap, dermatologist Faculty Dr. Julien Ringuet joins the Skin and Joints Podcast to tackle a question that comes up all the time in real-world atopic dermatitis care: once a patient is doing well, can we safely step down therapy without sending their skin into rebellion? Using newly presented data on abrocitinib dose down-titration from the JADE program, Dr. Ringuet walks through what happens when patients who respond to 200 mg transition to 100 mg for long-term maintenance—and what clinicians should do if disease control starts to slip. Spoiler: stepping down is not a cliff dive.  Along the way, we cover the “so what?” behind the numbers: who may be a good candidate for dose reduction, how to define loss of control beyond just visible skin lesions, why itch and sleep still deserve centre stage, and how shared decision-making can turn a dosing conversation into a true treatment partnership. This episode is for clinicians who want to move beyond poster reading and into practical, exam-room-ready conversations about JAK inhibitors, maintenance dosing, treat-to-target thinking, flare management, and individualized care in atopic dermatitis.   Learning Objectives 📚 After listening to this episode, listeners should be able to: Describe the clinical rationale for considering abrocitinib dose down-titration in selected patients with atopic dermatitis.  Interpret key long-term efficacy and flare data from the JADE Regimen/JADE Extend analyses in the context of real-world maintenance therapy.  Identify patient factors that may support or discourage dose reduction, including depth of response, flare history, adherence, follow-up reliability, quality-of-life burden, and patient preferences.  Explain how to counsel patients that step-down therapy is an option—not a guarantee—and that itch, sleep disruption, visible flare, and increased topical use can all signal loss of control.  Apply a treat-to-target mindset using both clinician-reported outcomes, such as EASI, IGA, and BSA, and patient-reported outcomes, including itch, sleep, satisfaction, and quality of life.  Recognize key caveats when applying clinical trial data to real-world practice, including responder-enriched populations, rescue therapy design, and as-observed analyses.  #SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #EczemaCare #Dermatology #PatientReportedOutcomes #JAKInhibitors #abrocitinib  #DermatologyEducation #MedicalEducation #HCPeducation #TreatToTarget #InflammatorySkinDisease #ClinicalData #DermTwitter #MedEd #Vodcast #PodcastEpisode #AADDenver #JAK #JAKinhibitor   ABOUT Dr. Julien Ringuet  Dermatologist, Quebec City, QC Dr Ringuet is a board certified dermatologist who practices in Quebec City as the principal investigator at the Centre de Recherche Dermatologique de Québec (CRDQ). He completed his medical training (MD) and his post graduate studies in dermatology form Laval University as well as a master in experimental medicine (MSc.) in the field of skin bioengineering at the Laboratoire d’Organogénèse Expérimentale de l’Université Laval (LOEX/CMDGT). Dr Ringuet and his team of the CRDQ are allowing patient access to quality and innovative clinical research focused on alopecia areata, atopic dermatitis, psoriasis and its variants and vitiligo.   Supported by an IME Grant from PFIZER.         📻www.skinandjoints.ca ✉️[email protected]

Skin, joints, and staying power—because in psoriasis, “getting clear” is only half the story. In this episode of the Skin and Joints Podcast 🎧, dermatologist Dr. Chih-ho Hong and rheumatologist Dr. May Kazem team up again for a lively, multidisciplinary deep dive into new 24-month real-world data from PSoHO 📊, an international prospective observational study of biologic-treated patients with moderate-to-severe psoriasis. The big question? Not just who gets patients clear ✨—but what gets them clear quickly ⏱️ and keeps them there for the long haul 🏃‍♂️. This analysis looks at 24-month effectiveness and durability across biologic classes, then zooms in 🔍 on several individual biologics from IL-17 to IL-23 and TNF-I . But here’s the catch—and it’s a clinically juicy one: durability was defined very stringentIly. Patients had to achieve PASI90 or PASI100 by week 12 🎯 and then maintain that same response at months 6, 12, 18, and 24 📆. In other words, this is not a “looked good once and disappeared” kind of outcome 👻. This is the biologic equivalent of showing up early, staying consistent, and never ghosting the follow-up visit ✅. Dr. Hong and Dr. Kazem bring the classic Skin and Joints perspective: how should clinicians interpret biologic class comparisons? Within class comparisons? And why does durability sound simple until you realize it rewards treatments that are both fast starters ⚡ and long-distance runners 🏃‍♀️? Expect practical pearls 💎, careful interpretation 🧠, and a reminder that real-world evidence is incredibly useful 🔬—as long as we read the fine print before declaring a winner 🏆. Based on the attached podcast conversation emphasizing multidisciplinary care, real-world caveats, patient priorities, and the importance of viewing psoriasis as more than “just skin.”    🎯 Learning Objectives After listening to this episode, learners should be able to: Describe the PSoHO study design 📊, including its role as an international, prospective, observational study of biologic-treated patients with moderate-to-severe psoriasis.  Explain 24-month effectiveness and durability ⏱️, including why maintaining PASI90 or PASI100 across multiple time points is a more demanding measure of sustained treatment success.  Interpret stringent durability outcomes with caution 🧠, recognizing that this definition favors therapies that achieve early clearance and then maintain it over time.  Compare biologic classes and individual agents 🔍, including how performance may be understood in the context of real-world treatment decisions.  Apply a multidisciplinary skin-and-joints lens , considering skin clearance, psoriatic arthritis risk, patient-reported impact, comorbidities, and treatment persistence.  Recognize the strengths and limitations of real-world observational data, including confounding by indication, patient selection, and why association does not automatically equal causation #SkinAndJoints #PsoriaticArthritis #Psoriasis #Dermatology #Rheumatology #Ixekizumab #PROSPIRIT #RealWorldEvidence #InflammatoryDisease #Biologics #bDMARDs #tsDMARDs #IL17 #MedEd #HCPeducation #DermRheum #PatientCentredCare #ClinicalPractice #Podcast #Vodcast Episode supported by an IME Grant from Eli Lilly.    ABOUT Dr. Chih-ho Hong, MD, FRCPC  Dermatologist, Vancouver, BC Dr. Hong is a board-certified dermatologist working in Greater Vancouver BC, Canada. He runs a busy office-based dermatology clinic with a focus on clinical research. He is a Clinical Associate Professor in the Department of Dermatology and Skin Sciences and teaches at St. Paul’s Hospital in Vancouver, where he is active staff. Dr. Hong is the past head of the BC Section of Dermatology, the current Economics representative for Dermatology at the BCMA, and is the past chair of the Education Committee of the Canadian Dermatology Association. He is also a past examiner in Dermatology for the Royal College of Physicians of Canada residency qualification examination.  He is currently the Canadian representative to SPIN (The Skin Inflammation and Psoriasis International Network) – spindermatology.org  Dr. Hong is active in clinical practice and dermatology research. His main clinical areas of interest are psoriasis and eczema. He has been an investigator in over 150 trials of treatments in dermatology and has over 50 peer reviewed publications. He has lectured locally, nationally, and internationally on dermatology treatments and has been an invited speaker at international dermatology congresses.   ABOUT Dr. May Kazem, MD, FRCPC  Rheumatologist, Vancouver, BC Dr. Mikameh “May” Kazem is a Canadian rheumatologist based in Vancouver, BC. She holds an undergraduate degree in biotechnology and a Master’s in Health Administration. She completed her Internal Medicine residency at the University of British Columbia, followed by Rheumatology fellowship training at the Schulich School of Medicine at Western University. Dr. Kazem practices general rheumatology in Vancouver and her areas of interest include management of patients with various inflammatory rheumatologic disorders and complex osteoporosis. She is also actively involved in medical education and patient advocacy, to promote awareness, knowledge-sharing, and improved care for individuals living with rheumatic conditions. 📻www.skinandjoints.ca ✉️[email protected]     📻www.skinandjoints.ca ✉️[email protected]

🎙️ 💡 When Skin and Joints Actually Mean… Skin AND Joints In this episode of the Skin and Joints Podcast, we bring together two expert voices — dermatologist Dr. Chih-ho Hong and rheumatologist Dr. May Kazem— for a true cross-specialty conversation on psoriatic arthritis care.  The focus? 🔍 The recent PRO-SPIRIT 12-month real-world study exploring the comparative effectiveness and persistence biologic/targeted synthetic DMARDs in patients with PsA. And spoiler alert 🚨: this isn’t just another “good skin drug vs good joint drug” debate. We dive into what the data means when the patient in front of you has plaques, pain, fatigue, stiffness, nail disease, possible axial symptoms, quality-of-life concerns… and a very real desire to just feel like themselves again.  What demonstrated a balanced signal across both skin and joint domains?   ✅Dr. Hong brings the dermatology lens: clearing skin matters deeply, and identifying PsA early can change the entire treatment pathway. ✅Dr. Kazem brings the rheumatology lens: PsA is heterogeneous, patient-reported outcomes matter, and treatment decisions need to account for competing domains like GI disease, uveitis, axial symptoms, and inflammatory arthritis burden. ✅Together, they remind us why PsA care works best when dermatology and rheumatology stop playing telephone ☎️ and start sitting at the same table. Preferably with coffee ☕. Possibly with a “skin and joints” drinking game.  🎧 Tune in for a practical, witty, and clinically grounded conversation on how real-world data can help refine real-world decisions.   🎯 Learning Objectives: After listening to this episode, learners will be able to: Describe the clinical relevance of the 12-month PRO-SPIRIT real-world study evaluating b/tsDMARDs in PsA. Discuss how dermatology and rheumatology perspectives differ — and overlap — when selecting advanced therapies for PsA. Identify key limitations of real-world comparative effectiveness studies, including confounding by indication and baseline phenotype differences. Apply a phenotype-driven approach to treatment selection across skin, joint, axial, enthesitis, nail, GI, and uveitis domains. Recognize the importance of repeat PsA screening in patients with psoriasis and the role of multidisciplinary co-management. Interpret treatment persistence and patient-reported outcomes in the context of real-world clinical practice.   #SkinAndJoints #PsoriaticArthritis #Psoriasis #Dermatology #Rheumatology #Ixekizumab #PROSPIRIT #RealWorldEvidence #InflammatoryDisease #Biologics #bDMARDs #tsDMARDs #IL17 #MedEd #HCPeducation #DermRheum #PatientCentredCare #ClinicalPractice #Podcast #Vodcast Episode supported by and IME Grant from Eli Lilly.    ABOUT Dr. Chih-ho Hong, MD, FRCPC  Dermatologist, Vancouver, BC Dr. Hong is a board-certified dermatologist working in Greater Vancouver BC, Canada. He runs a busy office-based dermatology clinic with a focus on clinical research. He is a Clinical Associate Professor in the Department of Dermatology and Skin Sciences and teaches at St. Paul’s Hospital in Vancouver, where he is active staff. Dr. Hong is the past head of the BC Section of Dermatology, the current Economics representative for Dermatology at the BCMA, and is the past chair of the Education Committee of the Canadian Dermatology Association. He is also a past examiner in Dermatology for the Royal College of Physicians of Canada residency qualification examination.  He is currently the Canadian representative to SPIN (The Skin Inflammation and Psoriasis International Network) – spindermatology.org  Dr. Hong is active in clinical practice and dermatology research. His main clinical areas of interest are psoriasis and eczema. He has been an investigator in over 150 trials of treatments in dermatology and has over 50 peer reviewed publications. He has lectured locally, nationally, and internationally on dermatology treatments and has been an invited speaker at international dermatology congresses.   ABOUT Dr. May Kazem, MD, FRCPC  Rheumatologist, Vancouver, BC Dr. Mikameh “May” Kazem is a Canadian rheumatologist based in Vancouver, BC. She holds an undergraduate degree in biotechnology and a Master’s in Health Administration. She completed her Internal Medicine residency at the University of British Columbia, followed by Rheumatology fellowship training at the Schulich School of Medicine at Western University. Dr. Kazem practices general rheumatology in Vancouver and her areas of interest include management of patients with various inflammatory rheumatologic disorders and complex osteoporosis. She is also actively involved in medical education and patient advocacy, to promote awareness, knowledge-sharing, and improved care for individuals living with rheumatic conditions. 📻www.skinandjoints.ca ✉️[email protected]     📻www.skinandjoints.ca ✉️[email protected]

🎙️✨ Melinda Knows Best at AAD Denver: Hands Down, Chronic Hand Eczema Is Getting a New Playbook 🖐️ Live from AAD 2026 in Denver 🏔️, a podcast favorite, Melinda Knows Best returns with Dr. Melinda Gooderham for a true post-game analysis🏀 of new chronic hand eczema data — and yes, this one is all about helping hands get back to doing what hands do best: opening jars 🥜, buttoning shirts 👔, holding coffee cups ☕, and generally not letting everyday life feel just like a clinical endpoint.  In this episode, we break down new pooled post-hoc data evaluating delgocitinib cream versus vehicle in adults with moderate-to-severe chronic hand eczema, with a practical twist: does prior systemic therapy exposure matter for patient success, especially when it comes to pain and itch? 🤔 We dive into: Does this data push delgocitinib earlier in the treatment algorithm for Melinda? What are the biggest critiques or caveats a dermatologist should keep in mind when looking at this data? Who is the real-world patient you would think about tomorrow after seeing this poster Well the chronic hand eczema treatment ladder may not be a one-way escalator anymore. 🪜🔄 Dr. Gooderham brings the real-world lens 👩‍⚕️: patients do not just want almost clear skin on a study scale — they want to work, cook, dress, sleep, and live without painful, itchy, fissured hands getting in the way. Because when it comes to chronic hand eczema, sometimes the most meaningful outcome is being able to open the peanut butter jar without negotiating with your skin first. 🥜😅 Learning objectives 📚 By the end of this episode, listeners will be able to: Summarize new AAD 2026 data evaluating delgocitinib cream in moderate-to-severe chronic hand eczema based on prior systemic therapy exposure.  Compare response patterns in systemic-naïve versus systemic-experienced patients.  Discuss the real-world clinical relevance of early itch and pain improvement in chronic hand eczema.  Identify key caveats of the analysis, including its post-hoc design, subgroup size, and 16-week timeframe.  Consider how delgocitinib may fit into evolving treatment algorithms for chronic hand eczema.    #SkinAndJointsPodcast #MelindaKnowsBest #AAD2026 #ChronicHandEczema #HandEczema #EczemaCare #Dermatology #DermatologyPodcast #Delgocitinib #MedicalEducation #HCPeducation #DermTwitter #AADDenver #SkinScience #TopicalTherapy #RealWorldDermatology  #IGA #HESD #itch #pain Episode supported by and IME Grant from LEO Pharma     ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology) Toronto, ON Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada. Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases. 📻www.skinandjoints.ca ✉️[email protected]     📻www.skinandjoints.ca ✉️[email protected]

🎙️✨ Isotretinoin + Clascoterone: Acne’s New Power Couple? When acne gets severe, isotretinoin usually enters the chat as the big gun.💥 But what happens when you pair it with topical clascoterone — the anti-androgen sidekick targeting the sebaceous gland from another angle? In this episode, we break down new real-world data from a multi-centre retrospective study comparing oral isotretinoin monotherapy versus combination isotretinoin + topical clascoterone for severe acne vulgaris and what the implications are for clinic. And yes — the combo arm brought some serious main-character energy.  Our expert guests unpack what this could mean in clinic:✨ faster clearance✨ improved tolerability✨ hormonal acne considerations✨ patient adherence realities✨ the ever-important goal of preventing scars before they happen Because in acne care, almost clear is nice… but clear-clear is the assignment. ✅ This conversation dives into the practical side: When should clascoterone be added? Which patients may benefit most? How do we keep regimens simple for younger patients already juggling isotretinoin, labs, moisturizers, sunscreen, and TikTok skincare detox?   Learning objectives: ✅ Review emerging data comparing isotretinoin monotherapy with isotretinoin plus topical clascoterone in severe acne vulgaris ✅ Discuss the potential clinical relevance of combination therapy for clearance, tolerability, and patient experience ✅ Explore practical approaches to integrating clascoterone into isotretinoin treatment plans ✅ Consider real-world limitations of retrospective data, including confounders, dosing variation, skincare use, and patient selection ✅ Reframe acne treatment goals beyond lesion counts to include scarring prevention, satisfaction, and long-term disease control 🎧  AAD 2026 coverage from the Mile High City. Special thanks Dr. Mohannad Abu-Hilal. #SkinAndJointsPodcast #AAD2026 #Dermatology #Acne #AcneVulgaris #Isotretinoin #Clascoterone #Winlevi #DermTwitter #MedEd #DermatologyEducation #SevereAcne #AcneScarring #SkinHealth #ClinicalDermatology #Vodcast #Podcast #HealthcareEducation   ABOUT Dr. Renée A. Beach MD FRCPC DABD Dermatologist | Toronto, ON   Dr. Renée A. Beach is a dermatologist practicing in Toronto for more than 10 years. She earned her medical doctor (MD) degree from McMaster University, followed by Dermatology residency at the University of Ottawa (FRCPC).  As an adjunct assistant professor at the University of Toronto, she teaches trainees in the Undergraduate MD program as well as postgraduate dermatology residents and has collaborated with them on various peer-reviewed publications. She is a trusted, regularly sought-after authority across media outlets and is the on-air dermatologist for CTVs The Social and Your Morning. On social media, she is active on Instagram (@dermabeach).  At her private office, DermAtelier on Avenue, she sees patients for medical and cosmetic treatments with the goal of delivering dermatologic excellence to patients of all skin tones and types About Dr. Irina Oroz, MD FRCPC DABD Dermatologist | Saskatoon, SK   Dr. Irina Oroz is a fellow of the Royal College of Physicians and Surgeons of Canada in Dermatology, a Diplomate of the American Board of Dermatology, and Assistant Clinical Professor of Dermatology at the University of Saskatchewan.  Currently she practices medical, surgical and cosmetic dermatology at Oroz Dermatology in Saskatoon. Her areas of interest lie in skin cancer, acne and psoriasis.  Dr. Oroz completed her medical degree at the University of Saskatchewan, prior to undertaking a five-year dermatology residency program at the University of Saskatchewan and University of Alberta. Her interest in the diagnosis and management of skin disease has been enhanced with elective training in USA, Australia and across Canada, with specialized training in Skin Cancer at the Royal Alexandra Hospital in Brisbane Australia, as well as medical education research in Edmonton.  Active in the medical community, Dr. Oroz is one of the founding members, as well as the current treasurer of the Saskatchewan Dermatology Association.  Supported by an IME Grant from SUN Pharma. 📻www.skinandjoints.ca ✉️[email protected]

🎙️✨ New Acne Data Just Dropped — and We’re Bringing the Post-Game Analysis from AAD 2026! 🏀 Live from Denver — the Mile High City — the Skin and Joints Podcast is breaking down new 52-week real-world acne data exploring the impact of clascoterone 1% on sebum reduction, acne improvement, tolerability, and what it actually means in day-to-day dermatology practice. Because let’s be honest: in acne care, it’s not just about lesion counts. Patients care about oiliness, shine, pores, irritation, post-inflammatory marks, and whether their treatment routine feels like a science experiment before bed. In this episode, Dr. Renée A. Beach and Dr. Irina Oroz (and a mystery guest co-host ;)) join the conversation to unpack the clinical relevance of the data — and why “treat-to-happy” might just be the endpoint patients really care about. We also get into the practical side: ✅How do you layer clascoterone with retinoids? ✅What does sebum reduction actually mean in clinic? ✅Is “zero irritation” too good to be true — or reflective of real-world experience? ✅And most importantly… is it pronounced sebometer or sebumeter?   From male acne patients who now have a topical anti-androgen option, to patients who have tried everything, to those who need a tolerable long-term acne strategy — this episode explores where the data meets the real world. Learning Objectives: ✅ Review new 52-week data on clascoterone 1% and sebum reduction in acne ✅ Discuss the clinical relevance of sebum, shine, oiliness, and patient-reported treatment success ✅ Evaluate long-term acne outcomes including IGA success, inflammatory and non-inflammatory lesion reduction, and tolerability ✅ Explore practical strategies for layering clascoterone with retinoids, benzoyl peroxide, and combo topical therapies ✅ Identify patient profiles who may benefit from topical anti-androgen therapy in real-world practice     ABOUT Dr. Renée A. Beach MD FRCPC DABD Dermatologist | Toronto, ON   Dr. Renée A. Beach is a dermatologist practicing in Toronto for more than 10 years. She earned her medical doctor (MD) degree from McMaster University, followed by Dermatology residency at the University of Ottawa (FRCPC).  As an adjunct assistant professor at the University of Toronto, she teaches trainees in the Undergraduate MD program as well as postgraduate dermatology residents and has collaborated with them on various peer-reviewed publications. She is a trusted, regularly sought-after authority across media outlets and is the on-air dermatologist for CTVs The Social and Your Morning. On social media, she is active on Instagram (@dermabeach).  At her private office, DermAtelier on Avenue, she sees patients for medical and cosmetic treatments with the goal of delivering dermatologic excellence to patients of all skin tones and types   About Dr. Irina Oroz, MD FRCPC DABD Dermatologist | Saskatoon, SK   Dr. Irina Oroz is a fellow of the Royal College of Physicians and Surgeons of Canada in Dermatology, a Diplomate of the American Board of Dermatology, and Assistant Clinical Professor of Dermatology at the University of Saskatchewan.  Currently she practices medical, surgical and cosmetic dermatology at Oroz Dermatology in Saskatoon. Her areas of interest lie in skin cancer, acne and psoriasis.  Dr. Oroz completed her medical degree at the University of Saskatchewan, prior to undertaking a five-year dermatology residency program at the University of Saskatchewan and University of Alberta. Her interest in the diagnosis and management of skin disease has been enhanced with elective training in USA, Australia and across Canada, with specialized training in Skin Cancer at the Royal Alexandra Hospital in Brisbane Australia, as well as medical education research in Edmonton.  Active in the medical community, Dr. Oroz is one of the founding members, as well as the current treasurer of the Saskatchewan Dermatology Association.  Supported by an IME Grant from SUN Pharma.       📻www.skinandjoints.ca ✉️[email protected]